Why Target Discovery Still Fails: Fixing The Biology Behind Poor Drug Targets

Target discovery is a common yet often underestimated point of failure in drug development. Even with today’s advanced genomics and computational modeling, the biopharmaceutical industry can still struggle to select targets that leverage biological insights to drive clinical success.

Too often, a promising hypothesis crumbles when its foundation is based on incomplete biological understanding, oversimplified disease models, or misinterpreted mechanistic context.

This collection covers target discovery successes and failures across diverse therapeutic areas, including infectious diseases, liver disorders, and oncology. Despite their differences, these case studies each demonstrate that success is not limited by data generation but by how well the data captures disease biology’s true complexity.